Compare AbCellera Biologics Inc (ABCL) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

LBTYK trades at $10.50, down 3.67% today, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $7.14B in 2025 despite $4.88B revenue, though recent Q1 2026 earnings beat expectations. Analyst sentiment remains positive with 69% buy ratings, while technical indicators show resistance at $11 and support at $10.

The outlook hinges on the planned 2027 Ziggo Group spin-off, which could unlock value, but persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. Near-term catalysts include Q2 2026 results in July, with the stock offering speculative upside if operational improvements materialize.